Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Trial Profile

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 15 Nov 2018.
    • 31 Aug 2018 Biomarkers information updated
    • 14 Aug 2018 Planned initiation date changed from 1 Apr 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top